{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:40:16Z","timestamp":1794508816980,"version":"4.9.1"},"reference-count":100,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.autrev.2025.103914","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T02:40:32Z","timestamp":1755744032000},"page":"103914","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["In search of biomarkers for prediction of drug treatment responses in rheumatoid arthritis: Lessons learned and future perspectives"],"prefix":"10.1016","volume":"24","author":[{"given":"Athanasia","family":"Dara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos I.","family":"Vlachogiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George E.","family":"Fragoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria G.","family":"Tektonidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros P.","family":"Sfikakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2025.103914_bb0005","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and Management of Rheumatoid Arthritis","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2025.103914_bb0010","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(23)01525-8","article-title":"Rheumatoid arthritis","volume":"402","author":"Di Matteo","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2025.103914_bb0015","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1093\/rheumatology\/kead106","article-title":"Mortality estimates and excess mortality in rheumatoid arthritis","volume":"62","author":"Black","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103914_bb0020","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/intimm\/dxu102","article-title":"Anti-TNF therapy: past, present and future","volume":"27","author":"Monaco","year":"2015","journal-title":"Int Immunol"},{"key":"10.1016\/j.autrev.2025.103914_bb0025","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1136\/annrheumdis-2016-210713","article-title":"Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"76","author":"Nam","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103914_bb0030","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000957.pub2","article-title":"Methotrexate for treating rheumatoid arthritis","author":"Lopez-Olivo","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2025.103914_bb0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103914_bb0040","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1093\/rheumatology\/kez213","article-title":"Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA","volume":"58","author":"Stouten","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103914_bb0045","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000993","article-title":"Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift","volume":"5","author":"Chatzidionysiou","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2025.103914_bb0050","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003714","article-title":"Comorbidities and chance of remission in patients with early rheumatoid arthritis receiving methotrexate as first-line therapy: a Swedish observational nationwide study","volume":"9","author":"Tidblad","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2025.103914_bb0055","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3899\/jrheum.2023-0334","article-title":"Rheumatoid arthritis: the continuum of disease and strategies for prediction, early intervention, and prevention","volume":"51","author":"O\u2019Neil","year":"2024","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103914_bb0060","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.hcl.2010.09.002","article-title":"Advances in the medical treatment of rheumatoid arthritis","volume":"27","author":"Kahlenberg","year":"2011","journal-title":"Hand Clin"},{"key":"10.1016\/j.autrev.2025.103914_bb0065","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/acr.24834","article-title":"Toward individualized prediction of response to methotrexate in early rheumatoid arthritis: a <scp>pharmacogenomics-driven<\/scp> machine learning approach","volume":"74","author":"Myasoedova","year":"2022","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2025.103914_bb0070","first-page":"15","article-title":"Deciphering the molecular landscape of rheumatoid arthritis offers new insights into the stratified treatment for the condition","author":"Chang","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103914_bb0075","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s13075-023-03222-4","article-title":"Machine learning and molecular subtype analyses provide insights into PANoptosis-associated genes in rheumatoid arthritis","volume":"25","author":"Li","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2025.103914_bb0080","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41590-019-0378-1","article-title":"Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry","volume":"20","author":"Zhang","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2025.103914_bb0085","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1365-3083.1992.tb03260.x","article-title":"T cells cloned from human rheumatoid synovial membrane functionally represent the Th 1 subset","volume":"35","author":"AMM","year":"1992","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.autrev.2025.103914_bb0090","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1136\/annrheumdis-2013-203566","article-title":"An immunological biomarker to predict MTX response in early RA","volume":"73","author":"Ponchel","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103914_bb0095","doi-asserted-by":"crossref","first-page":"19995","DOI":"10.1038\/s41598-019-56279-0","article-title":"Rheumatoid arthritis patients display B-cell dysregulation already in the na\u00efve repertoire consistent with defects in B-cell tolerance","volume":"9","author":"Wang","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2025.103914_bb0100","first-page":"15","article-title":"Integrated analysis of single-cell RNA-seq, bulk RNA-seq, Mendelian randomization, and eQTL reveals T cell-related nomogram model and subtype classification in rheumatoid arthritis","author":"Ding","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103914_bb0105","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1073\/pnas.1424792112","article-title":"Low expression of CD39 on regulatory T cells as a biomarker for resistance to methotrexate therapy in rheumatoid arthritis","volume":"112","author":"Peres","year":"2015","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.autrev.2025.103914_bb0110","first-page":"887","article-title":"Combination of B cell biomarkers as independent predictors of response in patients with rheumatoid arthritis treated with rituximab","volume":"33","author":"Tony","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2025.103914_bb0115","article-title":"Evaluation of B cell related markers and autoantibodies in rheumatoid arthritis patients treated with abatacept","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103914_bb0120","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1136\/ard-2022-223645","article-title":"Immunomics analysis of rheumatoid arthritis identified precursor dendritic cells as a key cell subset of treatment resistance","volume":"82","author":"Yamada","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103914_bb0125","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/art.27226","article-title":"Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-\u03b2\/\u03b1 ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort","volume":"62","author":"Mavragani","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103914_bb0130","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1136\/annrheumdis-2015-208001","article-title":"Increased pretreatment serum IFN-\u03b2\/\u03b1 ratio predicts non-response to tumour necrosis factor \u03b1 inhibition in rheumatoid arthritis","volume":"75","author":"Wampler Muskardin","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103914_bb0135","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1136\/annrheumdis-2022-222370","article-title":"Interferon-\u03b1-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming","volume":"81","author":"Cooles","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103914_bb0140","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/art.40810","article-title":"Profiling of gene expression biomarkers as a classifier of methotrexate nonresponse in patients with rheumatoid arthritis","volume":"71","author":"Plant","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2025.103914_bb0145","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/jcp.22153","article-title":"Interleukin-1\u03b2 induces ICAM-1 expression enhancing leukocyte adhesion in human rheumatoid arthritis synovial fibroblasts: involvement of ERK, JNK, AP-1, and NF-\u03baB","volume":"224","author":"Yang","year":"2010","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.autrev.2025.103914_bb0150","first-page":"10","article-title":"Intracellular adhesion Molecule-1 improves responsiveness to immune checkpoint inhibitor by activating CD8 + T cells. Advanced","author":"Lee","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.autrev.2025.103914_bb0155","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1007\/s10067-020-05043-1","article-title":"The predictive value of serum soluble ICAM-1 and CXCL13 in the therapeutic response to TNF inhibitor in rheumatoid arthritis patients who are refractory to csDMARDs","volume":"39","author":"Zhao","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103914_bb0160","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.autrev.2025.103914_bb0165","first-page":"779","article-title":"MDR-ABC transporters: biomarkers in rheumatoid arthritis","volume":"31","author":"M\u00e1rki-Zay","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2025.103914_bb0170","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.coph.2020.08.002","article-title":"Drug-resistance in rheumatoid arthritis: the role of p53 gene mutations, ABC family transporters and personal factors","volume":"54","author":"Zhang","year":"2020","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.autrev.2025.103914_bb0175","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1016\/j.gendis.2023.02.007","article-title":"The potential development of drug resistance in rheumatoid arthritis patients identified with p53 mutations","volume":"10","author":"Qiu","year":"2023","journal-title":"Genes Dis"},{"key":"10.1016\/j.autrev.2025.103914_bb0180","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/03009740310004333","article-title":"Multidrug resistance proteins in rheumatoid arthritis, role in disease-modifying antirheumatic drug efficacy and inflammatory processes: an overview","volume":"32","author":"Jansen","year":"2003","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103914_bb0185","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3899\/jrheum.180793","article-title":"Peripheral lymphocyte multidrug resistance activity as a predictive tool of biological therapeutic response in rheumatoid arthritis","volume":"46","author":"Toldi","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103914_bb0190","first-page":"15","article-title":"Proteomic profiling and biomarker discovery for predicting the response to PD-1 inhibitor immunotherapy in gastric cancer patients","author":"Sun","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.autrev.2025.103914_bb0195","doi-asserted-by":"crossref","first-page":"12513","DOI":"10.3390\/ijms252312513","article-title":"Proteomic analysis of biomarkers predicting treatment response in patients with head and neck cancers","volume":"25","author":"Zebene","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2025.103914_bb0200","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s44272-024-00027-7","article-title":"Proteomics efforts for hepatocellular carcinoma drug development","volume":"3","author":"Jia","year":"2024","journal-title":"Clinical Cancer Bull"},{"key":"10.1016\/j.autrev.2025.103914_bb0205","doi-asserted-by":"crossref","first-page":"6462","DOI":"10.1038\/s41467-024-50786-z","article-title":"Proteomic landscape of epithelial ovarian cancer","volume":"15","author":"Qian","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2025.103914_bb0210","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.3390\/cells12242808","article-title":"A peripheral blood signature of increased Th1 and myeloid cells combined with serum inflammatory mediators is associated with response to Abatacept in rheumatoid arthritis patients","volume":"12","author":"Goutakoli","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.autrev.2025.103914_bb0215","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1136\/ard.2008.093153","article-title":"Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis","volume":"68","author":"Trocme","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103914_bb0220","doi-asserted-by":"crossref","first-page":"176","DOI":"10.31083\/j.fbl2808176","article-title":"Different biomarkers of response to treatment with selective Jak-1 inhibitors in rheumatoid arthritis","volume":"28","author":"Benucci","year":"2023","journal-title":"Front Bioscience-Landmark"},{"key":"10.1016\/j.autrev.2025.103914_bb0225","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/cei\/uxac085","article-title":"Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response","volume":"210","author":"Valli","year":"2022","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2025.103914_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-023-03236-y","article-title":"Monocyte-derived transcriptomes explain the ineffectiveness of abatacept in rheumatoid arthritis","volume":"26","author":"Iwasaki","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2025.103914_bb0235","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10067-023-06814-2","article-title":"Identification of gene expression biomarkers to predict clinical response to methotrexate in patients with rheumatoid arthritis","volume":"43","author":"Palmowski","year":"2024","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103914_bb0240","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1002\/art.38671","article-title":"Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled","volume":"66","author":"Sellam","year":"2014","journal-title":"Open-Label Trial Arthritis & Rheumatology"},{"key":"10.1016\/j.autrev.2025.103914_bb0245","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13018-025-05494-9","article-title":"Unveiling new therapeutic horizons in rheumatoid arthritis: an in-depth exploration of circular RNAs derived from plasma exosomes","volume":"20","author":"Li","year":"2025","journal-title":"J Orthop Surg Res"},{"key":"10.1016\/j.autrev.2025.103914_bb0250","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nrrheum.2017.49","article-title":"Immunometabolism in early and late stages of rheumatoid arthritis","volume":"13","author":"Weyand","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2025.103914_bb0255","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3390\/jpm10040271","article-title":"Identification of metabolic biomarkers in relation to methotrexate response in early rheumatoid arthritis","volume":"10","author":"Gosselt","year":"2020","journal-title":"J Pers Med"},{"key":"10.1016\/j.autrev.2025.103914_bb0260","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1093\/rheumatology\/kez199","article-title":"Biomarkers identified by serum metabolomic analysis to predict biologic treatment response in rheumatoid arthritis patients","volume":"58","author":"Takahashi","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103914_bb0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163087","article-title":"Exploring the inflammatory Metabolomic profile to predict response to TNF-\u03b1 inhibitors in rheumatoid arthritis","volume":"11","author":"Cuppen","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2025.103914_bb0270","doi-asserted-by":"crossref","first-page":"7266","DOI":"10.1038\/s41598-021-86729-7","article-title":"Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics","volume":"11","author":"Maciejewski","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2025.103914_bb0275","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003575","article-title":"Diurnal production of cortisol and prediction of treatment response in rheumatoid arthritis: a 6-month, real-life prospective cohort study","volume":"10","author":"Yavropoulou","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2025.103914_bb0280","first-page":"11","article-title":"A Pauci-immune synovial Pathotype predicts inadequate response to TNF\u03b1-blockade in rheumatoid arthritis patients","author":"Nerviani","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103914_bb0285","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41591-022-01789-0","article-title":"Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial","volume":"28","author":"Rivellese","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2025.103914_bb0290","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.celrep.2019.07.091","article-title":"Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes","volume":"28","author":"Lewis","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.autrev.2025.103914_bb0295","doi-asserted-by":"crossref","first-page":"e648","DOI":"10.1016\/S2665-9913(23)00241-2","article-title":"Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials","volume":"5","author":"Rivellese","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2025.103914_bb0300","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/annrheumdis-2018-214539","article-title":"Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients","volume":"78","author":"Humby","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103914_bb0305","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1136\/annrheumdis-2019-215751","volume":"78","author":"Lliso-Ribera","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103914_bb0310","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1136\/ard.2007.080440","article-title":"The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor expression in the synovium","volume":"67","author":"Wijbrandts","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103914_bb0315","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","article-title":"Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial","volume":"397","author":"Humby","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2025.103914_bb0320","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41591-018-0300-7","article-title":"High-performance medicine: the convergence of human and artificial intelligence","volume":"25","author":"Topol","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2025.103914_bb0325","article-title":"Magician\u2019s corner: 9. Performance metrics for machine learning models. Radiol","volume":"3","author":"Erickson","year":"2021","journal-title":"Artif Intell"},{"key":"10.1016\/j.autrev.2025.103914_bb0330","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1093\/rheumatology\/keac645","article-title":"Machine learning identifies a profile of inadequate responder to methotrexate in rheumatoid arthritis","volume":"62","author":"Duquesne","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103914_bb0335","first-page":"8","article-title":"Machine learning predicts response to TNF inhibitors in rheumatoid arthritis: results on the ESPOIR and ABIRISK cohorts","author":"Bouget","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2025.103914_bb0340","first-page":"23","article-title":"Machine learning-based prediction model for responses of bDMARDs in patients with rheumatoid arthritis and ankylosing spondylitis","author":"Lee","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2025.103914_bb0345","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.3899\/jrheum.201626","article-title":"Predicting response to tocilizumab monotherapy in rheumatoid arthritis: a real-world data analysis using machine learning","volume":"48","author":"Johansson","year":"2021","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103914_bb0350","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s40744-021-00361-5","article-title":"Identification of a rule to predict response to Sarilumab in patients with rheumatoid arthritis using machine learning and clinical trial data","volume":"8","author":"Rehberg","year":"2021","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.autrev.2025.103914_bb0355","first-page":"23","article-title":"Machine learning model for identifying important clinical features for predicting remission in patients with rheumatoid arthritis treated with biologics","author":"Koo","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2025.103914_bb0360","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1093\/rheumatology\/keab521","article-title":"Early prediction of clinical response to anti-TNF treatment using multi-omics and machine learning in rheumatoid arthritis","volume":"61","author":"Yoosuf","year":"2022","journal-title":"Rheumatology (United Kingdom)"},{"key":"10.1016\/j.autrev.2025.103914_bb0365","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/art.41516","article-title":"Multiomics and machine learning accurately predict clinical response to adalimumab and Etanercept therapy in patients with rheumatoid arthritis","volume":"73","author":"Tao","year":"2021","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103914_bb0370","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/art.41056","article-title":"Machine learning to predict anti\u2013tumor necrosis factor drug responses of rheumatoid arthritis patients by integrating clinical and genetic markers","volume":"71","author":"Guan","year":"2019","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103914_bb0375","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.1038\/s41467-025-62032-1","article-title":"A longitudinal cohort study uncovers plasma protein biomarkers predating clinical onset and treatment response of rheumatoid arthritis","volume":"16","author":"He","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2025.103914_bb0380","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.trsl.2024.07.001","article-title":"A multi-biomarker panel for predicting tocilizumab response in rheumatoid arthritis patients","volume":"273","author":"Cho","year":"2024","journal-title":"Transl Res"},{"key":"10.1016\/j.autrev.2025.103914_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e22925","article-title":"Predicting anti-TNF treatment response in rheumatoid arthritis: an artificial intelligence-driven model using cytokine profile and routine clinical practice parameters","volume":"10","author":"Valdivieso Shephard","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.autrev.2025.103914_bb0390","first-page":"12","article-title":"Integrative clinical, molecular, and computational analysis identify novel biomarkers and differential profiles of anti-TNF response in rheumatoid arthritis","author":"Luque-T\u00e9var","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103914_bb0395","first-page":"18","article-title":"ATRPred: a machine learning based tool for clinical decision making of anti-TNF treatment in rheumatoid arthritis patients","author":"Prasad","year":"2022","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.autrev.2025.103914_bb0400","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6656121","article-title":"Anti-TROVE2 antibody determined by immune-related Array may serve as a predictive marker for adalimumab immunogenicity and effectiveness in RA","author":"Chen","year":"2021","journal-title":"J Immunol Res"},{"key":"10.1016\/j.autrev.2025.103914_bb0405","first-page":"11","article-title":"Blood pro-resolving mediators are linked with synovial pathology and are predictive of DMARD responsiveness in rheumatoid arthritis","author":"Gomez","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2025.103914_bb0410","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/art.21734","article-title":"The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial","volume":"54","author":"Westhovens","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103914_bb0415","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/10669817.2019.1589697","article-title":"Five good reasons to be disappointed with randomized trials","volume":"27","author":"Cook","year":"2019","journal-title":"J Man Manip Ther"},{"key":"10.1016\/j.autrev.2025.103914_bb0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2478\/rir-2020-0008","article-title":"Biomarkers for treatment response in rheumatoid arthritis: where are they?","volume":"1","author":"Zhao","year":"2020","journal-title":"Rheumatol Immunol Res"},{"key":"10.1016\/j.autrev.2025.103914_bb0425","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13075-018-1645-5","article-title":"Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK rheumatoid arthritis medication study (RAMS)","volume":"20","author":"Sergeant","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2025.103914_bb0430","series-title":"The elements of statistical learning\u2014Data mining, inference, and prediction","author":"Hastie","year":"2018"},{"key":"10.1016\/j.autrev.2025.103914_bb0435","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/jama.2019.20866","article-title":"Challenges to the reproducibility of machine learning models in health care","volume":"323","author":"Beam","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2025.103914_bb0440","first-page":"10","article-title":"Artificial intelligence in rheumatoid arthritis: potential applications and future implications","author":"Gilvaz","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.autrev.2025.103914_bb0445","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12916-018-1122-7","article-title":"From hype to reality: data science enabling personalized medicine","volume":"16","author":"Fr\u00f6hlich","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.autrev.2025.103914_bb0450","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1136\/annrheumdis-2021-221807","article-title":"Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis","volume":"81","author":"Kerschbaumer","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103914_bb0455","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41584-024-01115-7","article-title":"Advancing precision rheumatology through tissue and blood profiling","volume":"20","author":"Kalliolias","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2025.103914_bb0460","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s41467-024-45213-2","article-title":"Single-cell insights into immune dysregulation in rheumatoid arthritis flare versus drug-free remission","volume":"15","author":"Baker","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2025.103914_bb0465","doi-asserted-by":"crossref","first-page":"312","DOI":"10.31138\/mjr.251022.iac","article-title":"Identification and clinical correlation of circulating MAIT, \u03b3\u03b4 T, ILC3, and pre-inflammatory mesenchymal cells in patients with rheumatoid arthritis and Spondyloarthritis","volume":"35","author":"Kyriakidi","year":"2024","journal-title":"Mediterr J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103914_bb0470","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13075-015-0644-z","article-title":"Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy","volume":"17","author":"Nair","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2025.103914_bb0475","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.clim.2019.03.009","article-title":"DNA damage accumulation, defective chromatin organization and deficient DNA repair capacity in patients with rheumatoid arthritis","volume":"203","author":"Souliotis","year":"2019","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2025.103914_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102329","article-title":"Increased adenosine-to-inosine RNA editing in rheumatoid arthritis","volume":"106","author":"Vlachogiannis","year":"2020","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2025.103914_bb0485","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrc3721","article-title":"Principles and methods of integrative genomic analyses in cancer","volume":"14","author":"Kristensen","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.autrev.2025.103914_bb0490","first-page":"10","article-title":"Advancing personalized medicine through the application of whole exome sequencing and big data analytics","author":"Suwinski","year":"2019","journal-title":"Front Genet"},{"key":"10.1016\/j.autrev.2025.103914_bb0495","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s40744-021-00330-y","article-title":"A molecular signature response classifier to predict inadequate response to tumor necrosis factor-\u03b1 inhibitors: the NETWORK-004 prospective observational study","volume":"8","author":"Cohen","year":"2021","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.autrev.2025.103914_bb0500","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s40744-020-00226-3","article-title":"Clinical utility and cost Savings in Predicting Inadequate Response to anti-TNF therapies in rheumatoid arthritis","volume":"7","author":"Bergman","year":"2020","journal-title":"Rheumatol Ther"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225001752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225001752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T12:27:49Z","timestamp":1765024069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997225001752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":100,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1568997225001752"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103914","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In search of biomarkers for prediction of drug treatment responses in rheumatoid arthritis: Lessons learned and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103914","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103914"}}